Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Double-blind, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of TX000045 After 24 Weeks of Treatment in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (PH-HFpEF)

Next Previous
Trial Profile

A Phase 2, Double-blind, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of TX000045 After 24 Weeks of Treatment in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (PH-HFpEF)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TX-000045 (Primary)
  • Indications Pulmonary hypertension
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms APEX
  • Sponsors Tectonic Therapeutic

Most Recent Events

  • 20 Mar 2025 According to a Tectonic Therapeutic media release, company look forward to presenting detailed results at an upcoming meeting as well as continuing to advance both the APEX Phase 2 trial and Part B of the Phase 1b trial.
  • 07 Nov 2024 According to a Tectonic Therapeutic media release, First subject dosed with TX000045 in APEX Phase 2 clinical trial in early October.
  • 19 Sep 2024 According to a Tectonic Therapeutic media release, Screening for the Phase 2 APEX clinical trial has been initiated and topline results are anticipated in 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top